RESEARCH PROFILE
BPC-157
Synthetic Gastric Pentadecapeptide • Tissue Repair Research
BPC-157 is a synthetic 15 amino acid peptide derived from a sequence first identified in human gastric juice. Research has focused primarily on tissue repair, tendon and ligament models, vascular signaling, gastrointestinal injury, and inflammatory pathways.
Most of the evidence remains preclinical, with only limited pilot-level human research currently available.
INVESTIGATIONAL • NOT FDA APPROVED • PRIMARILY PRECLINICAL EVIDENCE
BPC-157 AT A GLANCE
Category
Tissue repair and inflammatory research peptide
Compound Type
Synthetic 15 amino acid pentadecapeptide
Research Focus
Tendon • Ligament • Gut • Vascular signaling • Inflammation
Evidence Base
Predominantly animal and laboratory research
Human Evidence
Limited pilot studies and small case series
Regulatory Status
Not FDA approved
IMPORTANT DISTINCTION
BPC-157 has an unusually large body of animal and mechanistic research compared with its very small human evidence base.
Preclinical studies have reported effects involving:
Angiogenesis
Cell migration
Tendon and ligament healing
Nitric oxide signaling
Gastrointestinal tissue protection
Inflammatory pathways
However, these findings have not been confirmed through large randomized human clinical trials.
BPC-157 should therefore not be described as a clinically proven treatment for tendon, ligament, muscle, gastrointestinal, inflammatory, or other injuries.
WHAT IS BPC-157?
BPC-157 stands for Body Protection Compound 157.
It is a synthetic 15 amino acid peptide derived from a sequence originally identified in human gastric juice.
Unlike many peptide compounds that mimic endocrine hormones, BPC-157 is primarily studied in the context of tissue protection, wound healing, gastrointestinal biology, vascular signaling, and inflammatory response.
Research has investigated BPC-157 in models involving:
Tendon injury
Ligament injury
Muscle injury
Gastrointestinal damage
Blood vessel formation
Peripheral nerve injury
Inflammatory signaling
One unusual characteristic described in the literature is its relative stability in gastric environments compared with many peptides.
This has contributed to research involving both injectable and gastrointestinal exposure models.
However, the biological mechanisms observed in laboratory and animal studies have not yet been established as clinically meaningful therapeutic effects in humans.
MECHANISM OF ACTION
BPC-157 does not have one definitively established human molecular target.
Instead, preclinical research suggests that it may influence several pathways involved in tissue repair, vascular function, and cellular migration.
ANGIOGENESIS
One of the most frequently studied mechanisms is angiogenesis, the formation of new blood vessels.
Animal and cellular studies suggest BPC-157 may influence vascular endothelial growth factor signaling, including VEGFR2.
Formation of new microvasculature could theoretically support injured tissue by improving local blood supply.
This remains primarily a preclinical mechanism.
VEGFR2 & AKT-eNOS SIGNALING
Research cited in your Project profile reports activation of the VEGFR2-Akt-eNOS pathway.
eNOS participates in production of nitric oxide within vascular endothelial cells.
Nitric oxide influences blood-vessel tone, circulation, endothelial function, and aspects of tissue repair.
CELL MIGRATION
BPC-157 has also been reported to influence FAK-paxillin signaling, which participates in cellular attachment and migration.
In wound-healing models, these pathways may help fibroblasts and endothelial cells migrate into damaged tissue.
ERK1/2 & JAK-2 SIGNALING
Preclinical studies cited in the Project source also describe effects involving:
ERK1/2
JAK-2
These intracellular signaling systems participate in cellular survival, migration, proliferation, and tissue response to injury.
INFLAMMATORY SIGNALING
Animal research suggests BPC-157 may influence inflammatory pathways including NF-κB and NOS2.
These findings have contributed to interest in BPC-157 for inflammatory and tissue-injury research.
IMPORTANT MECHANISM LIMITATION
These pathways provide plausible biological explanations for observations in laboratory and animal models.
They do not establish that the same mechanisms produce clinically meaningful tissue repair in humans.
WHAT THE RESEARCH SHOWS
TENDON & LIGAMENT RESEARCH
Some of the most frequently cited BPC-157 research involves tendon and ligament injury models.
Animal studies have reported:
Improved tendon-to-bone healing
Enhanced tendon fibroblast migration
Changes in collagen organization
Improved biomechanical measures in some injury models
These studies provide much of the rationale behind BPC-157's reputation as a “healing peptide.”
However, they are predominantly animal studies.
GASTROINTESTINAL RESEARCH
BPC-157 has also been extensively investigated in experimental gastrointestinal models.
Preclinical research has examined:
Gastric lesions
Intestinal injury
Inflammatory gastrointestinal damage
Gastrointestinal anastomosis healing
Gut-brain signaling
These findings remain largely preclinical and should not be presented as proof that BPC-157 treats human gastrointestinal disease.
VASCULAR & WOUND-HEALING RESEARCH
Laboratory and animal research has reported effects involving:
Angiogenesis
Endothelial cell migration
Nitric oxide signaling
Local blood-flow regulation
Wound-healing pathways
These findings provide mechanistic support for continued tissue-repair research.
HUMAN PILOT EVIDENCE
Your Project profile identifies a small number of human pilot reports.
These include:
A 12-patient knee-pain case series
A 12-woman interstitial cystitis pilot study
A two-adult intravenous safety pilot
These studies represent direct human exposure and preliminary observations, but their sample sizes are extremely small.
They cannot establish efficacy, optimal dosing, long-term safety, or broad clinical benefit.
2025 SYSTEMATIC REVIEW
Your Project profile cites a 2025 systematic review of BPC-157 in orthopedic sports medicine.
The review concluded that the human evidence remains insufficient to support clinical recommendations.
That conclusion is important because it places the extensive animal literature in the proper clinical context.
PHARMACOKINETIC RESEARCH
Animal pharmacokinetic research indicates that BPC-157 has a relatively short plasma half-life.
Your Project source cites rat and dog research reporting a plasma half-life of under approximately 30 minutes following IM or IV administration.
Short plasma exposure does not necessarily mean biological signaling ends immediately, but human pharmacokinetic data remain inadequate.
IMPORTANT EVIDENCE LIMITATION
There is currently no published Phase 2 or Phase 3 human randomized controlled trial establishing BPC-157 as an effective treatment.
The strongest evidence remains preclinical.
Animal findings involving tendon healing, angiogenesis, inflammation, gastrointestinal protection, or nerve recovery should therefore not be represented as established human clinical outcomes.
SAFETY & RESEARCH CONSIDERATIONS
BPC-157's human safety database remains limited.
The absence of large clinical trials means uncommon, delayed, or long-term adverse effects may not yet be characterized.
HUMAN PILOT SAFETY
Your Project profile identifies a 2025 intravenous pilot involving two adults who received 10 mg and 20 mg IV BPC-157.
The investigators reported no adverse effects on evaluated:
Cardiac markers
Hepatic markers
Renal markers
Thyroid markers
Glucose biomarkers
A separate small knee-pain pilot also reported that the intervention was generally well tolerated.
These findings are preliminary because the sample sizes were extremely small.
INJECTION-SITE EFFECTS
Community reports most commonly describe mild local effects such as:
Redness
Irritation
Small bumps at the injection site
These community observations are not equivalent to a controlled clinical adverse-event database.
ANGIOGENESIS & CANCER
One of BPC-157's most discussed theoretical safety questions comes directly from one of its proposed repair mechanisms.
Preclinical studies suggest BPC-157 may promote angiogenesis.
Because tumor growth can also depend on development of new blood vessels, your Project profile identifies active or prior cancer as an unresolved theoretical concern.
There is currently insufficient human evidence to determine the clinical significance of this mechanism.
This does not establish that BPC-157 causes cancer.
BLOOD PRESSURE & NITRIC OXIDE
BPC-157 affects nitric oxide signaling in animal research.
Because nitric oxide influences vascular tone, people using medications that affect blood pressure or vascular signaling represent an important area of potential interaction uncertainty.
PREGNANCY & LACTATION
Your Project profile identifies no published human reproductive or lactation safety data.
PRODUCT QUALITY
An important safety issue is independent of the peptide's biological mechanism.
Much of the BPC-157 available in the United States is sold through research-use or gray-market channels.
Potential concerns include:
Incorrect concentration
Contamination
Degradation
Mislabeling
Sterility problems
Lot-to-lot variability
Analytical testing can characterize specific tested samples, but it does not establish overall clinical safety.
REGULATORY CONTEXT
BPC-157 IS NOT FDA APPROVED
BPC-157 is not an FDA-approved drug for any indication.
There is no FDA-approved branded BPC-157 prescription product.
FDA COMPOUNDING HISTORY
Your Project profile documents an important regulatory change in 2026.
BPC-157 had previously appeared in FDA's 503A Category 2, which included substances identified as raising significant safety concerns during evaluation.
Effective April 22, 2026, FDA removed BPC-157 from Category 2.
Importantly, your Project source explains that this removal occurred because the original Category 2 nomination was withdrawn, not because FDA made a positive determination that BPC-157 is safe or effective.
PHARMACY COMPOUNDING ADVISORY COMMITTEE
Your Project profile further notes that FDA scheduled review of BPC-157-related substances by the Pharmacy Compounding Advisory Committee on July 23, 2026 in connection with potential inclusion on the 503A Bulks List.
These regulatory processes concern compounding policy.
They do not constitute FDA approval of BPC-157 as a drug.
INTERNATIONAL REGULATORY CONTEXT
Your Project profile notes regulatory activity outside the United States, including Australia and New Zealand.
The regulatory treatment of BPC-157 varies by jurisdiction and should not be generalized from one country to another.
ANTI-DOPING STATUS
BPC-157 has been included on the World Anti-Doping Agency Prohibited List under category S0 since 2022.
Competitive athletes subject to WADA or similar anti-doping rules should not assume that research status makes the compound permissible.
IMPORTANT REGULATORY DISTINCTION
Removal from an FDA compounding-risk category does not equal FDA approval.
Compounding review does not establish clinical efficacy.
Research availability does not establish medical suitability.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation only for specific samples and lots that can be matched to corresponding laboratory reports.
BPC-157
Laboratory
Optiq Health Labs
Lot
kizen72826
Sample ID
1267.OPT.260910
Report Date
September 18, 2026
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Reported Net Content
5.14 mg/vial
Reported Purity
99.4%
Identity
LC-MS Confirmation • BPC-157 Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth COAs-2(2)
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
The laboratory states that its findings relate only to the sample received and tested and do not represent or warrant the quality, composition, or characteristics of another sample, lot, batch, product, or material. COAs-2(2)
A Certificate of Analysis does not establish clinical safety, efficacy, medical suitability, or FDA approval.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
SELECTED RESEARCH & REFERENCES
Chang CH, Tsai WC, Hsu YH, Pang JHS.
The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
Journal of Applied Physiology. 2011.
Preclinical tendon-healing and cellular migration research.
Hsieh MJ, Liu HT, Wang CN, et al.
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
Journal of Molecular Medicine. 2017.
Mechanistic research involving VEGFR2 and angiogenic signaling.
Hsieh MJ, Lee CH, Chueh HY, et al.
Research examining BPC-157, vascular tone, and Src-Caveolin-1-eNOS signaling.
Mechanistic vascular research.
He L, Feng D, Guo H, et al.
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs.
Frontiers in Pharmacology. 2022.
Preclinical pharmacokinetic and tissue-distribution research.
Sikiric P, Staresinic M, Barisic I, et al.
Research examining stable gastric pentadecapeptide BPC-157 and gastrointestinal protection.
Vukojevic J, Milavic M, Perovic D, et al.
Research examining BPC-157 and central nervous system biology.
Vasireddi R, Hameed H, Salata MJ, et al.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS Journal. 2025.
Systematic review concluding that human evidence remains insufficient to support clinical recommendations.
Lee R, Padgett B.
Intra-articular BPC-157 research involving multiple forms of knee pain.
Alternative Therapies in Health and Medicine. 2021.
Small human pilot/case-series evidence.
Lee R, Walker C, Ayadi F.
Research examining BPC-157 symptoms in patients with interstitial cystitis.
Alternative Therapies in Health and Medicine. 2024.
Small human pilot evidence.
Lee R, Walker C, Ayadi F.
Safety of intravenous infusions of BPC157 in humans: A Pilot Study.
Alternative Therapies in Health and Medicine. 2025.
Very small preliminary human safety study.
Xu W, Sun C, Han F, et al.
Preclinical safety evaluation of BPC-157.
U.S. Food & Drug Administration
Updated 503A bulk drug substances materials concerning BPC-157.
World Anti-Doping Agency
World Anti-Doping Code International Standard Prohibited List.
EVIDENCE NOTE
BPC-157 has a substantial preclinical research literature involving tissue repair, vascular signaling, gastrointestinal biology, and inflammation.
Human evidence remains limited to very small studies and case series.
The animal and mechanistic literature should therefore not be presented as established proof that BPC-157 heals human tendons, ligaments, muscles, nerves, gastrointestinal tissue, or other injuries.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish BPC-157 as safe or effective for personal use.
BPC-157 is not FDA approved for any therapeutic indication.
Most published BPC-157 research is preclinical. Although limited human pilot data now exist, there are no published Phase 2 or Phase 3 randomized human trials establishing clinical efficacy, optimal dosing, or long-term safety.
Findings involving tissue repair, angiogenesis, tendon or ligament healing, gastrointestinal protection, inflammation, or other biological effects in animal and laboratory studies should not be interpreted as established clinical benefits in humans.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.